ATE230989T1 - Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems - Google Patents
Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystemsInfo
- Publication number
- ATE230989T1 ATE230989T1 AT93920438T AT93920438T ATE230989T1 AT E230989 T1 ATE230989 T1 AT E230989T1 AT 93920438 T AT93920438 T AT 93920438T AT 93920438 T AT93920438 T AT 93920438T AT E230989 T1 ATE230989 T1 AT E230989T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- sec
- anabasein
- derivatives
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93842792A | 1992-08-31 | 1992-08-31 | |
PCT/US1993/008192 WO1994005288A1 (en) | 1992-08-31 | 1993-08-31 | Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE230989T1 true ATE230989T1 (de) | 2003-02-15 |
Family
ID=25471422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93920438T ATE230989T1 (de) | 1992-08-31 | 1993-08-31 | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems |
Country Status (9)
Country | Link |
---|---|
US (1) | US5741802A (de) |
EP (1) | EP0659078B1 (de) |
JP (1) | JP3034953B2 (de) |
KR (1) | KR100272614B1 (de) |
AT (1) | ATE230989T1 (de) |
AU (1) | AU674541B2 (de) |
CA (1) | CA2142610C (de) |
DE (1) | DE69332641T2 (de) |
WO (1) | WO1994005288A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
JP3034953B2 (ja) * | 1992-08-31 | 2000-04-17 | ユニバーシティー オブ フロリダ リサーチ ファンデーション,インコーポレーテッド | 神経系の変性疾患の治療に有用なアナバセイン誘導体 |
US5723477A (en) * | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5705512A (en) * | 1994-11-10 | 1998-01-06 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5703100A (en) * | 1994-11-10 | 1997-12-30 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5594011A (en) * | 1994-11-10 | 1997-01-14 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5677459A (en) * | 1994-11-10 | 1997-10-14 | Sibia Neurosciences, Inc. | Methods for the preparation of modulators of acetylcholine receptors |
US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5794887A (en) | 1995-11-17 | 1998-08-18 | Komerath; Narayanan M. | Stagnation point vortex controller |
DE69825605T2 (de) | 1997-05-29 | 2005-09-15 | H. Lundbeck A/S | Behandlung der schizophrenie und der psychose |
US6708055B2 (en) * | 1998-08-25 | 2004-03-16 | University Of Florida | Method for automated analysis of apical four-chamber images of the heart |
US6346124B1 (en) | 1998-08-25 | 2002-02-12 | University Of Florida | Autonomous boundary detection system for echocardiographic images |
US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US6448276B1 (en) | 2000-05-17 | 2002-09-10 | Inspire Pharmaceuticals, Inc. | Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
JP2006501246A (ja) * | 2002-08-30 | 2006-01-12 | メモリー・ファーマシューティカルズ・コーポレイション | 神経変性疾患の治療において有用なアナバセイン誘導体 |
KR101129933B1 (ko) | 2002-09-25 | 2012-03-23 | 메모리 파마슈티칼스 코포레이션 | 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도 |
US7273872B2 (en) * | 2002-12-06 | 2007-09-25 | The Feinstein Institute For Medical Research | Inhibition of inflammation using α 7 receptor-binding cholinergic agonists |
US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP4995075B2 (ja) | 2004-03-25 | 2012-08-08 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、ベンゾイソチアゾール、ベンズイソキサゾール、ならびにそれらの調製および使用 |
JP2007530586A (ja) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
US20050288333A1 (en) * | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
EP2298410B1 (de) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Behandlung von entzündlichen Erkrankungen durch elektrische Stimulation des Vagusnervs |
EP1891036A4 (de) | 2005-06-07 | 2010-08-04 | Univ Florida | Selektive liganden für alpha-7-nikotinrezeptoren |
US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
US7662965B2 (en) | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
JP2011516489A (ja) | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
US20110237597A1 (en) * | 2008-05-23 | 2011-09-29 | Zesiewicz Theresa A | Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |
EP2355893B1 (de) | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Vorrichtungen zur optimierung der elektrodenplatzierung für antientzündungsstimulationen |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
AU2010284282A1 (en) * | 2009-08-21 | 2012-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Controlled-release formulations of anabaseine compounds and uses thereof |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
EP2593426B1 (de) * | 2010-07-12 | 2014-08-20 | F.Hoffmann-La Roche Ag | 1-hydroxyimino-3-phenyl-propane |
US9440948B2 (en) | 2010-09-03 | 2016-09-13 | University Of Florida Research Foundation, Inc. | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11096932B2 (en) | 2016-09-29 | 2021-08-24 | The Uab Research Foundation | Methods and compositions for increasing mucus clearance |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
WO2021249608A2 (en) * | 2020-06-09 | 2021-12-16 | Elkazaz Mohamed Fadly Abd El Ghany | A novel medicament for immune modulation and treating chronic or hyper inflammation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3275625A (en) * | 1966-09-27 | Derivatives of | ||
US3426130A (en) * | 1960-12-19 | 1969-02-04 | Squibb & Sons Inc | Compositions containing a benzothiadiazinesulfonamide 1,1-dioxide |
US3247213A (en) * | 1961-04-12 | 1966-04-19 | Shell Oil Co | Heterocyclic nitrogen compounds |
US3265573A (en) * | 1962-07-27 | 1966-08-09 | Squibb & Sons Inc | Benzothiadiazinesulfonamide-1, 1-dioxide composition |
US4155909A (en) * | 1977-06-13 | 1979-05-22 | Philip Morris Incorporated | 2-Alkyl nicotinoids and processes for their production |
US4195645A (en) * | 1978-03-13 | 1980-04-01 | Celanese Corporation | Tobacco-substitute smoking material |
US4965074A (en) * | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
CA2105071C (en) * | 1991-03-01 | 2002-05-14 | John A. Zoltewicz | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
JP3034953B2 (ja) * | 1992-08-31 | 2000-04-17 | ユニバーシティー オブ フロリダ リサーチ ファンデーション,インコーポレーテッド | 神経系の変性疾患の治療に有用なアナバセイン誘導体 |
US5488049A (en) * | 1993-12-10 | 1996-01-30 | Fidia - Georgetown Institute For The Neuro-Sciences | Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents |
-
1993
- 1993-08-31 JP JP06507391A patent/JP3034953B2/ja not_active Expired - Fee Related
- 1993-08-31 AU AU50979/93A patent/AU674541B2/en not_active Ceased
- 1993-08-31 CA CA002142610A patent/CA2142610C/en not_active Expired - Lifetime
- 1993-08-31 DE DE69332641T patent/DE69332641T2/de not_active Expired - Lifetime
- 1993-08-31 US US08/392,763 patent/US5741802A/en not_active Expired - Lifetime
- 1993-08-31 AT AT93920438T patent/ATE230989T1/de not_active IP Right Cessation
- 1993-08-31 WO PCT/US1993/008192 patent/WO1994005288A1/en active IP Right Grant
- 1993-08-31 KR KR1019950700698A patent/KR100272614B1/ko not_active IP Right Cessation
- 1993-08-31 EP EP93920438A patent/EP0659078B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH08509458A (ja) | 1996-10-08 |
AU5097993A (en) | 1994-03-29 |
WO1994005288A1 (en) | 1994-03-17 |
EP0659078A1 (de) | 1995-06-28 |
KR950702829A (ko) | 1995-08-23 |
EP0659078A4 (de) | 1996-04-24 |
AU674541B2 (en) | 1997-01-02 |
US5741802A (en) | 1998-04-21 |
CA2142610C (en) | 2003-09-16 |
DE69332641D1 (de) | 2003-02-20 |
EP0659078B1 (de) | 2003-01-15 |
KR100272614B1 (ko) | 2000-11-15 |
DE69332641T2 (de) | 2003-11-27 |
JP3034953B2 (ja) | 2000-04-17 |
CA2142610A1 (en) | 1994-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE230989T1 (de) | Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems | |
BR9709501A (pt) | Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto | |
LTIP919A (en) | Drugs and process for preparing thereof | |
ATE198830T1 (de) | Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems | |
ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
DE60022050T2 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
ATE168007T1 (de) | Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
HUP0001062A2 (hu) | NAALADáz gátló hatású foszfinsavszármazékokat tartalmazó gyógyászati készítmények | |
HUT73433A (en) | Process for preparing pharmaceutical compositions containing riluzole for treating aids-related neural disorders | |
ATE325610T1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
TR199700711T1 (xx) | Ciltten ge�erek v�cuda giren form�lasyon. | |
ATE455773T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
ATE216891T1 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
ATE189385T1 (de) | Verwendung von benzonaphtalene-derivaten zur herstellung eines arzneimittels zur behandlung von krankheiten des nervensystems | |
NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
GR3034661T3 (en) | Use of Selegiline in vetenary medicine. | |
IL117083A0 (en) | Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical agents containing these compounds | |
DE69827706D1 (de) | 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems | |
DE59409813D1 (de) | Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen | |
DE69413554D1 (de) | IMIDAZO [1,5-a] CHINOLINE ZUR BEHANDLUNG VON ANGSTZUSTÄNDEN UND SCHLAFSTÖRUNGEN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |